Create SD Q1 FY2027: Revenue expands 6.5%, margins squeeze amid costs

Create SD Holdings posted strong revenue growth in its first quarter covering June to August 2026. Revenue rose 6.5% year on year to 129.54 billion yen, driven by enhanced competitiveness in existing stores, new store openings, and the consolidation of its food supermarket business.

Profitability, however, faced headwinds. Operating income fell 4.1% to 5.404 billion yen. Ordinary income declined 4.7% to 5.63 billion yen, while net income for the quarter dropped 5.2% to 3.788 billion yen. The company is currently navigating a "revenue growth, profit decline" scenario.

The pressure on margins stems from rising costs for pharmaceuticals and fresh food, alongside poor sales of seasonal merchandise due to unfavorable weather. In an industry marked by intensifying price competition, the key challenge lies in maintaining profitability while controlling selling, general, and administrative expenses.

The drugstore segment dominates revenue, with its performance dictating overall results. Pharmaceutical sales grew 7.6% to 32.908 billion yen, while food product sales rose 5.8% to 55.379 billion yen.

A notable highlight is the growth in the prescription pharmacy segment. Rising prescription prices and strengthened addition fees drove this segment's revenue up 14.0% to 17.424 billion yen.

The supermarket segment saw a surge of 295.5%, adding 2.153 billion yen in revenue following the June consolidation of subsidiary Yaofuku. The care services business also expanded steadily, aided by higher occupancy rates in senior housing and day-care facilities. Geographically, Kanagawa Prefecture accounts for roughly 60% of total sales, highlighting its continued importance.

Profitability challenges persist due to rising procurement costs for food and daily necessities. As Create SD continues its "Everyday Low Price" (EDLP) strategy amidst intense competition, balancing cost control with sales efficiency will be critical to restoring margins.

The balance sheet remains robust. Total assets at the end of the first quarter stood at 249.872 billion yen, a decrease of 5.477 billion yen from the previous fiscal year-end, primarily due to inventory adjustments.

The equity ratio held strong at 62.0%, up 1.6 percentage points from the prior year-end of 60.4%. This high level of self-financing reflects a conservative management style that relies less on debt, enhancing resilience against economic fluctuations. Cash and deposits totaled 32.273 billion yen, down roughly 13% year on year, as funds were allocated to new store openings and capital expenditure.

For the full fiscal year ending May 2027, the company forecast an annual dividend of 96 yen per share, with payouts of 48 yen each at the second quarter end and fiscal year-end. Net income per share is projected at 263.15 yen. The number of treasury shares remained unchanged, supporting sustainable capital formation through retained earnings.

The environment for achieving the "NextSTAGE2030" strategy is growing more difficult. The primary risk is the intensifying price competition and aggressive store expansion by competitors across traditional industry boundaries. As major players engage in mergers and acquisitions, Create SD must solidify its unique competitive advantages.

Macroeconomic factors also pose risks. Persistent inflation may slow personal consumption, particularly for price-sensitive categories like fresh food and daily goods, threatening both sales volume and margins. Additionally, geopolitical tensions and uncertainty surrounding U.S. trade policies could increase supply chain costs.

On the operational front, changes in pharmaceutical regulations and prescription fee revisions require strategic adaptation. Beyond streamlining pharmacy operations, strengthening ties with medical institutions is essential for differentiation. While optimizing its store portfolio through five new openings and one closure in the quarter, the company must maintain existing store competitiveness.